Medical Cannabis Patients Cut Opioid Use From 40mg to Under 3mg Daily Over One Year

Among 102 chronic pain patients co-prescribed cannabinoids alongside opioids, median opioid consumption dropped from 40 mg/day to 2.7 mg/day at one year, significantly lower than the 42.3 mg/day maintained by 53 opioid-only controls. However, 46 of 102 cannabis patients dropped out compared to only 1 of 53 controls.

Prospective observational study at two Australian pain clinics. One cohort (n=102) received opioids plus medical cannabis (titrated to median 15mg THC/15mg CBD daily); the other (n=53) received opioids only. Assessed at 12 months with intention-to-treat analysis.

The opioid reduction was dramatic, but the 45% dropout rate reveals that medical cannabis as an opioid-sparing strategy only works for a subset of patients. Both the promise and the limitation are important for realistic expectations.

The opioid crisis has driven interest in cannabis as an opioid-sparing tool. This real-world data shows it can work dramatically for some patients, but the high dropout rate tempers enthusiasm and highlights the need to identify who will benefit.

Observational, not randomized. High dropout rate in cannabis group (45%) creates selection bias among completers. Non-blinded. Small sample size. Single clinic setting in Australia. Reasons for dropout not fully detailed.